2.05
Schlusskurs vom Vortag:
$2.15
Offen:
$2.18
24-Stunden-Volumen:
1.97M
Relative Volume:
1.33
Marktkapitalisierung:
$144.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.50M
KGV:
-0.8542
EPS:
-2.4
Netto-Cashflow:
$-114.31M
1W Leistung:
-7.24%
1M Leistung:
-15.98%
6M Leistung:
-61.90%
1J Leistung:
-78.49%
Nkarta Inc Stock (NKTX) Company Profile
Firmenname
Nkarta Inc
Sektor
Branche
Telefon
(925) 407-1049
Adresse
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Vergleichen Sie NKTX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
NKTX
Nkarta Inc
|
2.05 | 144.67M | 0 | -117.50M | -114.31M | -2.40 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-10-09 | Eingeleitet | Rodman & Renshaw | Buy |
2024-08-14 | Hochstufung | Raymond James | Outperform → Strong Buy |
2024-03-22 | Herabstufung | Raymond James | Strong Buy → Outperform |
2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
2022-07-28 | Eingeleitet | Needham | Buy |
2022-07-18 | Eingeleitet | SVB Leerink | Outperform |
2022-03-11 | Eingeleitet | Raymond James | Outperform |
2022-03-08 | Eingeleitet | H.C. Wainwright | Buy |
2022-01-06 | Eingeleitet | William Blair | Outperform |
2021-11-18 | Eingeleitet | SMBC Nikko | Outperform |
2021-07-16 | Eingeleitet | Oppenheimer | Outperform |
2020-08-04 | Eingeleitet | Cowen | Outperform |
2020-08-04 | Eingeleitet | Evercore ISI | Outperform |
2020-08-04 | Eingeleitet | Mizuho | Buy |
2020-08-04 | Eingeleitet | Stifel | Buy |
Alle ansehen
Nkarta Inc Aktie (NKTX) Neueste Nachrichten
Leerink Partnrs Forecasts Nkarta FY2029 Earnings - MarketBeat
Leerink Partnrs Comments on Nkarta FY2024 Earnings - Defense World
Leerink Partnrs Comments on Nkarta FY2029 Earnings - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Stock Performance Spotlight: Nkarta Inc (NKTX) Ends the Day at 2.09, Down by -3.69 - The Dwinnex
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of “Buy” by Brokerages - Defense World
A new trading data show Nkarta Inc (NKTX) is showing positive returns. - SETE News
Vasculitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | R-Pharm Overseas, Abbvie, Toleranzia, Ambulero, Visterra, CytoDyn - The Globe and Mail
Monitoring Nkarta Inc (NKTX) after recent insider movements - Knox Daily
The Potential Rise in the Price of Trane Technologies plc (TT) following insiders activity - Knox Daily
Closing Figures: Nkarta Inc (NKTX)’s Negative Finish at 2.17, Down -7.26 - The Dwinnex
TANG CAPITAL MANAGEMENT LLC Increases Stake in Nkarta Inc - GuruFocus.com
What Does Nkarta Inc’s (NASDAQ: NKTX) Future Hold? - Stocks Register
Nkarta's chief medical officer sells $19,003 in stock - MSN
Nkarta CEO Paul Hastings sells $38,231 in stock - MSN
Nkarta executive sells shares worth $12,843 - MSN
Nkarta's chief technical officer sells $16,383 in stock By Investing.com - Investing.com Australia
Nkarta chief legal officer Alicia Hager sells $21,084 in stock - Investing.com India
Nkarta chief legal officer Alicia Hager sells $21,084 in stock By Investing.com - Investing.com Australia
Nkarta, Inc. (NASDAQ:NKTX) Insider Sells $19,003.60 in Stock - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) CEO Sells $38,231.60 in Stock - MarketBeat
JPMorgan Chase & Co. Purchases 761,349 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta executive sells shares worth $12,843 By Investing.com - Investing.com South Africa
Nkarta's chief medical officer sells $19,003 in stock By Investing.com - Investing.com South Africa
Nkarta's chief technical officer sells $16,383 in stock - MSN
Nkarta, Inc. (NASDAQ:NKTX) Receives $15.00 Consensus Target Price from Analysts - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of “Buy” by Brokerages - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Shares Acquired by Barclays PLC - Defense World
Jane Street Group LLC Lowers Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Geode Capital Management LLC Raises Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Franklin Resources Inc. Takes Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta, Inc.: Trying To Find Space In A Crowded Place - Seeking Alpha
Nkarta, Inc. (NASDAQ:NKTX) Shares Bought by Barclays PLC - Defense World
Thinking about buying stock in Agile Therapeutics, Evoke Pharma, Warner Bros Discovery, Nkarta, or Sky Harbour? - Marketscreener.com
State Street Corp Purchases 15,569 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Finanzdaten der Nkarta Inc-Aktie (NKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):